EXO1是肺内存T细胞的关键基因,对肺腺癌具有诊断和预测价值
Zhuoqi Li1, Xiaoyan Lin2,3, Yuanhui Yang2
1Department of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 250011, Jinan, P.R. China.
Scientific reports
|February 1, 2025
概括
在肺腺癌 (LUAD) 中,EXO1的表达很高,作为危险因素,影响预后. 它的表达与临床特征和免疫细胞透相关,影响免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 肺腺癌 (LUAD) 是癌症死亡的一个重要原因.
- 组织内存T (TRM) 细胞在抗癌免疫中至关重要.
- 以前,EXO1被确定为LUAD预后中TRM细胞的核心基因.
研究的目的:
- 研究EXO1在LUAD瘤微环境中的作用.
- 评估EXO1在LUAD中的诊断和预后潜力.
- 探索EXO1与免疫细胞透和免疫治疗反应的关联.
主要方法:
- 来自公共数据库的RNA表达,DNA甲基化,CNV和突变数据的生物信息分析.
- 在LUAD样本中使用EXO1的免疫组织化学染色进行验证.
- 与临床特征,免疫细胞透和患者结果的相关性分析.
主要成果:
- 在LUAD组织中,EXO1异常过度表达.
- 高EXO1表达是LUAD患者的风险因素,与TNM阶段相关.
- EXO1准确地将LUAD与正常组织区分开来,并与免疫细胞透有关.
- 高EXO1表达对接受抗PD-1/PD-L1免疫治疗的患者的结果产生负面影响.
- EXO1突变与更糟糕的生存率 (DSS,DFI,PFI) 有关.
结论:
- EXO1 是一个潜在的 LUAD 诊断和预后生物标志物.
- EXO1表达影响瘤的免疫微环境和免疫疗法的有效性.
- 准EXO1可能为LUAD提供治疗策略.
更多相关视频
相关概念视频
Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


